This FOA invites applications for projects designed to test the effectiveness of microphysiological systems (MPS), also called “tissue chip,” technology, for clinical trial frameworks by demonstrating their applied use in clinical trial planning and execution, addressing both safety and efficacy in late-stage preclinical studies. This approach is to provide evidence of the utility of tissue chip technology for precision medicine in informing trial design, establishing recruitment criteria and stratification of patient populations in identifying the best responders to candidate therapeutics.
Deadlines:
RFA-TR-19-014 Expiration Date October 10, 2019
Budget requests are limited to $500,000 direct cost per year.
The scope of the proposed project should determine the project period. The maximum project period is 5 years limited to up to 2 years for the UG3 phase, and up to 3 years for the UH3 phase.
